Sangamo Therapeutics, Inc. (NASDAQ:SGMO) today announced changes to its research and development organization.
Going forward, research and development will each be managed as separate functions. A search for a Head of Development is underway. Jason Fontenot, Senior Vice President, Cell Therapy, will assume the role of Interim Head of Research. The heads of research and development will report to CEO Sandy Macrae.
"The changes we are announcing today are designed to increase the speed and efficiency of the clinical translation of our ground-breaking science into genomic medicines," said Sandy Macrae, CEO of Sangamo. "Managing research and development separately will allow us to industrialize zinc finger protein engineering, to retain our strength in basic research that has led to our broad and growing pipeline of genomic medicine candidates, and to add new capabilities in late-stage clinical and product development."
Sangamo today also announced the departure of Adrian Woolfson, Executive Vice President of R&D. "Adrian contributed a great deal to Sangamo," Macrae said. "With endless energy and excitement, he inspired many with his scientific understanding and his belief in the potential of our technology. We wish him every success as he pursues his next endeavor."